dMCL1-2

N/A

Report date: 2021/12/09 16:42:07

Base Information

Drug NamedMCL1-2
Drug Alias NamedMCL1-2dMCL-1-2
ClassificationSmall molecules > Proteolysis-Targeting Chimera (PROTAC)
Mechanisms of ActionProteolysisInduced myeloid leukemia cell differentiation protein Mcl-1 inhibitors
TargetsInduced myeloid leukemia cell differentiation protein Mcl-1
Therapy Area/IndicationsLeukemia, Myelogenous, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Calgary
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Calgary
Inactive CompaniesN/A
Active IndicationsLeukemia, Myelogenous, Chronic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A